Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

11.48
-0.2200-1.88%
Volume:586.04K
Turnover:6.76M
Market Cap:977.02M
PE:-3.01
High:11.83
Open:11.73
Low:11.29
Close:11.70
52wk High:23.29
52wk Low:6.56
Shares:85.11M
Float Shares:55.47M
Volume Ratio:0.42
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:2.28
PE(LYR):-3.25

Loading ...

MoonLake Immunotherapeutics - Proceeds to Fund Sonelokimab Activities and General Corporate Purposes

THOMSON REUTERS
·
Jun 23

MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street

TIPRANKS
·
Jun 23

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Jun 23

MoonLake Shares Rise on Late-Stage Data for Hidradenitis Suppurativa Treatment

Dow Jones
·
Jun 22

MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials

TIPRANKS
·
Jun 22

MoonLake says Phase 3 VELA trials show sonelokimab hits 67% HiSCR75 at Week 52 in hidradenitis suppurativa

Reuters
·
Jun 22

MoonLake Announces Week 52 Results of Sonelokimab From Its Phase 3 Vela Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

THOMSON REUTERS
·
Jun 22

MoonLake CFO Matthias Bodenstedt sells $351,804 of common shares

Reuters
·
Jun 19

MoonLake CSO Kristian Reich disposes of 150,000 shares for $2.85 million

Reuters
·
Jun 18

Moonlake Immunotherapeutics shareholders approve amended 2022 equity incentive plan, adding 5 million shares

Reuters
·
Jun 10

Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)

TIPRANKS
·
Jun 09

Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX

TIPRANKS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Jun 08

MoonLake Immunotherap Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

MoonLake Immunotherapeutics (MLTX) Valuation After FDA Progress On Sonelokimab Draws Fresh Investor Attention

Simply Wall St.
·
Jun 06

MoonLake Immunotherapeutics signs commercial supply pact with Vetter Pharma for prefilled application systems

Reuters
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)

TIPRANKS
·
May 20

LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
May 16

MoonLake Immunotherap Is Maintained at Buy by Needham

Dow Jones
·
May 12

Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
May 12